Bavarian Nordic Awarded $1.57 Billion Contract for Smallpox Vaccines

BARDA Contract Will Replenish Inventory for Future Manufacturing

Bavarian Nordic has announced a significant contract award from the US Biomedical Advanced Research and Development Authority (BARDA) for the procurement of its smallpox vaccine, Jynneos. The contract, valued at $1.57 billion, will help replenish the government's inventory of bulk vaccine, ensuring future manufacturing and supply of freeze-dried vaccines. The company emphasized that the contract will have no impact on its overall financial guidance for the year.

Replenishing Public Stockpiles

The contract is part of BARDA's efforts to strengthen the nation's pandemic preparedness. The smallpox vaccine is considered an essential component of strategic national stockpiles, providing protection against a highly contagious and potentially fatal disease. The replenishment of vaccine inventory will ensure adequate supplies for emergency response and vaccination campaigns in the event of an outbreak.

Manufacturing and Supply

The contract will support Bavarian Nordic's manufacturing and supply capabilities for Jynneos. The vaccine is currently freeze-dried, which allows for long-term storage and easy administration. The company's manufacturing facilities will be utilized to produce the vaccine in bulk, ensuring a reliable supply for future needs.